An okra polysaccharide (Abelmoschus esculentus) reinforced green hydrogel based on guar gum and poly-vinyl alcohol double network for controlled release of nanocurcumin.

A novel green hydrogel (PGCO) of Okra (Abelmoschus esculentus) mucilage-reinforced poly-vinyl alcohol-guar gum (PG) cross-linked by citric acid containing nanocurcumin (NC) as a model drug is reported. The citric acid (CA) cross-linked hydrogel (PGC) without okra is also prepared. The hydrogels are characterized using FTIR, XRD, FE-SEM, and TGA techniques. Okra reinforced green hydrogel (PGCO) provided comparable swelling behaviour with better mechanical and thermal properties compared to the neat PGC hydrogel. Network parameters of PGC and PGCO hydrogels are estimated using Flory-Rehner equation and strong correlation between the cross-link density and swelling behaviour is established. 45.68 % NC loading in the PGCO hydrogel is achieved. Release study in phosphate buffer (PB) of pH 7.4 provided sustained release of NC over a period of 100 h. The release study of NC followed primarily the Korsmeyer-Peppas model with less-Fickian diffusional character (n < 0.5). The average diffusion coefficients of NC and curcumin are found to be 3.52 × 10-5 cm2 s-1, and 3.43 × 10-5 cm2 s-1 respectively demonstrating the quick release of NC in early time, which is a pre-requisite in drug delivery. The study provides initial evidence of the usefulness of okra mucilage in green hydrogel development and drug delivery applications.

Highly stable silver nanoparticles containing guar gum modified dual network hydrogel for catalytic and biomedical applications.

Although many preparation methods have been reported till date, it is still a great challenge to prepare silver nanoparticles (AgNPs) that simultaneously possess high stability and enhanced applicability. We report a rapid and efficient synthesis of AgNPs containing polyvinyl alcohol (PVA)-guar gum (GG) smart hydrogel composite, which exhibited pH-dependent swelling and enhanced mechanical strength. The AgNPs were synthesized in situ in the PVA-GG hydrogel from various concentrations of the AgNO3 precursor solution in the presence of NaBH4. Stable AgNPs (90 days) of 10-20 nm uniformly dispersed in PVA-GG hydrogel was obtained. Simultaneously, at the optimum concentration of AgNO3 (0.01 M), the tensile strength and elongation at break were enhanced by 74 % and 11 %, and swelling capacity was increased by 18 % as compared to PVA-GG hydrogel (control). The PVA-GG-AgNPs hydrogel composite exhibited excellent catalytic activity and antibacterial property, which makes them a suitable candidate for industrial applications.

Controlled release of tamoxifen citrate encapsulated in cross-linked guar gum nanoparticles.

Natural polysaccharides, due to their outstanding merits, have received more and more attention in the field of drug delivery. In the present study tamoxifen citrate, TMX (a non-steroidal antiestrogenic drug) loaded guar gum nanoparticles, GG NPs, crosslinked with glutaraldehyde were prepared for treatment of breast cancer. An oil in water (o/w) emulsion polymer cross-linking method was employed for preparation of blank and drug loaded sustained release nature biodegradable nanoparticles. Prepared nanoparticles were characterized by morphology in scanning electron microscope (SEM), size distribution in transmission electron microscope (TEM), TMX loading by high performance liquid chromatography (HPLC) and in vitro drug release characteristics. An overall sustained release of the drug from the biodegradable nanoparticles was observed in in vitro release studies. The release of TMX from GG NPs was found to be effected by guar gum and glutaraldehyde concentration. Regression coefficient (R(2)) analysis suggested that the predominant mechanism behind the drug release from the nanoparticles was time dependent release and diffusion. In vivo studies on female albino mice demonstrated maximum uptake of the drug by mammary tissue after 24h of administration with drug loaded guar gum nanoparticles in comparison with that with the tablet form of the drug. These findings demonstrate that controlled release of TMX from GG NPs could be a potential alternative pharmaceutical formulation in passive targeting of TMX in breast cancer treatments.